[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stress-urinary-incontinence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stress-urinary-incontinence":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,51,80,102,131,152,181,211,234,255,276,298,326,363,390,411,439,470,496,518,540,567,588,609,633],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100622747","synchronized-core-pelvic-floor-activation-in-urinary-incontinence-100622747",false,"NCT07387640","Synchronized Core-Pelvic Floor Activation in Urinary Incontinence","Synchronized Activation of Core and Pelvic Floor Muscles: A More Effective Strategy for Urinary Incontinence?","Inclusion Criteria:\n\n* Aged between 18 and 65 years\n* Diagnosed with stress, urge, or mixed urinary incontinence\n* Pelvic floor muscle strength grade ≥ 3 according to the Modified Oxford Scale\n* At least one episode of urinary leakage within the last month\n\nExclusion Criteria:\n\n* Pregnancy\n* Childbirth within the previous 6 weeks\n* Severe pelvic organ prolapse\n* Active vaginal or urinary tract infection\n* Presence of neurological or psychiatric disorders\n* Malignancy\n* Inability to cooperate with assessments or interventions","FEMALE","18 Years","65 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to investigate whether co-activation of the pelvic floor and core muscles improves treatment outcomes in individuals with urinary incontinence. Participants diagnosed with stress, or mixed urinary incontinence will undergo a 12-week pelvic floor physiotherapy program, with or without additional core muscle co-activation exercises. Changes in urinary incontinence severity, pelvic floor muscle function, core muscle activation, and quality of life will be evaluated.",[28,29,30,31],"Urinary Incontinence,Stress","Stress Urinary Incontinence","Mixed Incontinence Due to Prolapse of Female Genital Organ","Urinary Incontinence",[33,34,35,36,37],"Pelvic floor muscle training","Core stability exercises","Core Muscle Co-activation","Pelvic floor physiotherapy","Surface Electromyography","NOT_YET_RECRUITING","2026-06-30",{"date":41,"type":42},"2026-07-01","ACTUAL",{"date":44,"type":22},"2026-08-30",{"date":46,"type":22},"2027-08-30",{"name":48,"class":49},"Bezmialem Vakif University","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100426144","ethicon-pelvic-mesh-post-market-clinical-follow-up-registry-100426144","NCT04829175","Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry","A Long Term Prospective Observational Post Market Clinical Follow-Up (PMCF) Registry of Ethicon Gynecare Pelvic Mesh Products for The Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse","Inclusion Criteria:\n\nPatients who satisfy all of the following criteria will be considered eligible for enrollment in this registry:\n\nSUI\n\n1. Stress urinary incontinence symptoms\n2. Urodynamic stress incontinence confirmed with urodynamic testing\n3. Female patient ≥ 21 years of age\n4. Desired surgical correction of SUI using synthetic pubo-urethral vaginal sling\n5. Planned surgery for primary SUI\n6. Patient able and willing to participate in follow-up\n7. Patient or authorized representative has signed the approved Informed consent POP\n\n1\\. Uterine or vaginal vault prolapse symptoms 2. Urodynamic testing (optional) 3. Female patient ≥ 21 years of age 4. Desired surgical correction of POP using synthetic mesh 5. Planned surgery for uterine or vaginal vault prolapse with or without concomitant SUI surgery 6. Patient able and willing to participate in follow-up 7. Patient or authorized representative has signed the approved Informed consent\n\nExclusion Criteria\n\nPatients meeting any of the following criteria will be considered not eligible for enrollment in this registry:\n\n1. Physical or psychological condition which would impair registry participation or are unwilling or unable to participate in all required registry visits and are unable to complete the questionnaires\n2. Any pre-operative or intra-operative findings identified by the surgeon that may preclude the use of registry products\n3. History of previous synthetic, biologic or fascial sub-urethral sling (SUI) or pelvic mesh (POP)\n4. Pregnancy or plans for future pregnancy\n5. History of bleeding diathesis or current anti-coagulation therapy which cannot be suspended peri-operatively according to site's standard practice\n6. Current genitourinary fistula or urethral diverticulum\n7. Reversible cause of incontinence (i.e. drug effect) for SUI only\n8. Severe vaginal atrophy\n9. History of pelvic irradiation therapy\n10. Contraindication to surgery","21 Years",{"count":60,"type":22},1000,"OBSERVATIONAL","The objective of this post market, clinical registry is to evaluate the performance of the products of the TVT family of products or vaginal vault or uterine prolapse repair (with laparotomic or laparoscopic approach including robotic assisted) using either Gynemesh PS Mesh or Artisyn Mesh in women undergoing surgery for SUI and POP.",[29,64],"Pelvic Organ Prolapse",[29,64,66,67],"SUI","POP","RECRUITING","2026-06-25",{"date":71,"type":42},"2026-06-26",{"date":73,"type":42},"2022-04-11",{"date":75,"type":22},"2038-03-31",{"name":77,"class":78},"Ethicon, Inc.","INDUSTRY",10,{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":50},"100641712","effect-of-different-pelvic-floor-loading-techniques-on-women-with-stress-urinary-incontinence-100641712","NCT07661264","Effect of Different Pelvic Floor Loading Techniques on Women With Stress Urinary Incontinence","Inclusion Criteria:\n\n* All women are suffering from Stress urinary incontinence.\n* Their age will range from 30-40 years.\n* Their body mass index will range from 25-30 kg\u002Fm2.\n* They are multiparous women (2-3 times).\n\nExclusion Criteria:\n\n* Patient with denervated pelvic floor muscle, urinary tract infection, severe prolapse of pelvic organs, fibroid uterus, or intrauterine devices.\n* Renal disease, pulmonary illness, chronic cough, and constipation.\n* Underwent surgery for stress urinary incontinence.\n* Other types of urinary incontinence (e.g., urge incontinence and mixed incontinence).\n* Diabetic patients.\n* Patient with anatomic changes (ectopic ureter, genito-urinary fistula)\n* Patient with knee or back symptoms (Osteoarthritis or lumbar disc).","30 Years","40 Years",{"count":89,"type":22},40,[25],"The purpose of this study is to compare the effects of different pelvic floor loading techniques (graduated positions versus graduated weights) on women with stress urinary incontinence.",[29],"2026-06-19",{"date":95,"type":42},"2026-06-24",{"date":97,"type":22},"2026-06",{"date":99,"type":22},"2026-12-30",{"name":101,"class":49},"Cairo University",{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":130},"100552987","trial-of-transurethral-bulking-agent-injection-versus-single-incision-sling-for-stress-urinary-incontinence-100552987","NCT06480227","Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence","A Randomized Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence","BASIS","Inclusion Criteria:\n\n* Women ≥ 21 years\n* For \\> 3 months, bothersome SUI (response of somewhat, moderately, or quite a bit) without UUI or stress-predominant MUI. For those with equal bother of UUI and SUI, clinician determination that SUI is more severe\u002Fsignificant than UUI is required.\n* A positive cough stress test on standardized non-invasive testing or urodynamic SUI within the past 18 months.\n* Normal PVR \\\u003C 150 mL\n* Candidate for either study procedure as determined by treating surgeon\n* Available for up to 3 years.\n* Agrees to randomization.\n\nExclusion Criteria:\n\n* Anterior\u002Fapical vaginal prolapse beyond the hymen (\\>0 on POPQ)\n* Urge-predominant mixed UI despite stable therapy\n* Advanced UUI\u002FOAB 3rd line therapy treatment within 1 year of enrollment.\n* Planned hysterectomy, urethral or anterior\u002Fapical surgeries s requiring general anesthesia at the time of SUI treatment, during the last 6 months, or planned within the next 12 months.\n* Malignancy or history of radiation of the pelvis\n* Pregnant, post-partum, breast feeding or plans for pregnancy within 1 year\n* Incomplete emptying (PVR \\> 150mL)\n* Prior anti-incontinence procedure\n* Neurogenic bladder\n* Unwilling to continue current UUI treatment until completion of primary outcome at 12 months\n* Prior adverse reaction to synthetic mesh or urethral bulking material\n* Chronic bladder or pelvic pain conditions (e.g., Interstitial cystitis, painful bladder syndrome, fibromyalgia, chronic pelvic pain, etc.)\n* Active treatment for SUI with a pessary. For those using a pessary or other SUI support device, a 3-week washout period should occur prior to assessing baseline measures.",{"count":111,"type":22},358,[25],"This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after conservative care.\n\nThe Primary Aim is to determine the comparative effectiveness (as defined by \"much\" or \"very much\" better on PGI-I) of transurethral bulking agent (TBA) \\[for 1 or 2 injections in 12 months\\] vs. single-incision sling (SIS) 12 months after treatment intervention in women with predominant stress urinary incontinence (SUI).",[29,31,115],"Mixed Urinary Incontinence",[31,117,118,119],"Pelvic Floor Disorders","Single Incision Sling","Transurethral Bulking Agent","2026-06-04",{"date":122,"type":42},"2026-06-08",{"date":124,"type":42},"2024-08-28",{"date":126,"type":22},"2030-12-31",{"name":128,"class":129},"NICHD Pelvic Floor Disorders Network","NETWORK",7,{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},"100426158","post-market-clinical-follow-up-study-on-tvt-abbrevo-continence-system-100426158","NCT04829357","Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System","A Long Term Prospective Post Market Clinical Follow-up (PMCF) of the GYNECARE TVT ABBREVO® Continence System for the Treatment of Stress Urinary Incontinence","Inclusion Criteria:\n\nSubjects who satisfy all of the following criteria will be considered eligible for enrollment in this study:\n\n1. Stress urinary incontinence symptoms\n2. Diagnostic evaluation, a positive cough stress rest, to confirm diagnosis of stress urinary incontinence.\n3. Female subjects ≥ 21 years of age requiring treatment of SUI\n4. Desired surgical correction of stress urinary incontinence using synthetic sub-urethral vaginal slings\n5. Planned surgery for primary stress incontinence without concomitant prolapse surgery\n6. Patient able and willing to participate in follow-up\n7. Subject or authorized representative has signed the approved informed consent\n\nExclusion Criteria\n\nSubjects meeting any of the following criteria will be considered not eligible for enrollment in this study:\n\n1. Physical or psychological condition which would impair study participation or are unwilling or unable to participate in all required study visits and are unable to complete the questionnaires\n2. Any pre-operative or intra-operative findings identified by the surgeon that may preclude the use of study product\n3. History of previous synthetic, biologic or fascial sub-urethral sling\n4. Pregnancy or plans for future pregnancy\n5. History of bleeding diathesis or current anti-coagulation therapy which cannot be suspended peri-operatively according to site's standard practice.\n6. Current genitourinary fistula or urethral diverticulum\n7. Reversible cause of incontinence (i.e. drug effect)\n8. Contraindication to surgery",{"count":139,"type":22},195,"The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT ABBREVO® Continence System in women undergoing Mid-urethral sling surgery for Stress Urinary Incontinence (SUI).",[29],[143,66],"Gynecare TVT ABBREVO® Continence System",{"date":145,"type":42},"2026-06-05",{"date":147,"type":42},"2021-09-09",{"date":149,"type":22},"2038-12-31",{"name":77,"class":78},4,{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":50},"100574035","believe-trial-bulking-versus-sling-for-treating-stress-urinary-incontinence-at-the-time-of-vaginal-prolapse-repair-believe-100574035","NCT06754046","BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)","BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair","BELIEVE","Inclusion Criteria:\n\n* Women ≥ 18 years of age.\n* Have diagnosis of symptomatic or occult stress urinary incontinence (SUI) as noted in their electronic health record (EHR).\n* Proof of positive testing for SUI via cough stress test (CST) and\u002For Urodynamic (UDS) testing,\n* Patients that are planning and eligible for native tissue prolapse repair and for both Retropubic Midurethral Sling (RP-MUS) and Polyacrylamide Hydrogel (PAHG)\n\nExclusion Criteria:\n\n* Patients undergoing pelvic organ prolapse repair using mesh or biologic augmentation other than patient's own tissue\n* Patient anticipating difficulty with completing 24-month follow-up\n* Anticipation of pregnancy within subsequent 24-months or \\\u003C18 months post-partum\n* Hemoglobin A1c \\>10.0% within the past 3-months\n* Current smoker \\> 1 pack per week\n* History of neurogenic bladder\n* Current use of any catheterization including but not limited to, intermittent catheterization, indwelling Foley catheter, or suprapubic catheter\n* Post-void residual \\>150 mL felt to not be due to obstruction for prolapse\n* Prior history of any anti-incontinence procedure including but not limited to any synthetic sling, fascial sling, Burch colposuspension or its variants, and urethral bulking\n* Previous history of any pelvic radiation\n* Patient receiving a planned concurrent procedure at the time of prolapse repair.",{"count":161,"type":22},476,[25],"The goal of this clinical trial is to learn if retropubic midurethral sling (RP-MUS) or bulkamide injection (PAHG) at the time of pelvic organ prolapse repair is better from the patient's perspective. The main questions it aims to answer are:\n\nWhat is the average difference in the urogenital distress inventory (UDI) long form score 24 months after surgery for each procedure? Which procedure has the fewest complications and lowest short- and long-term morbidity profile?\n\nParticipants will:\n\nBe blinded and randomized to one of two procedures for the duration of the study, 24 months.\n\nComplete 6 total visits for the clinical trial including validated questionnaires.\n\nFew participants will be selected to complete a qualitative interview at 3 timepoints over 24 month duration of the study.",[29,165],"Vaginal Prolapse",[167,168,169,170,171],"midurethral sling","bulkamide","polyacrylamide hydrogel","urethral bulking","retropubic sling","2026-05-27",{"date":174,"type":42},"2026-06-01",{"date":176,"type":42},"2025-05-01",{"date":178,"type":22},"2029-04",{"name":180,"class":49},"University Hospitals Cleveland Medical Center",{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":188,"minAge":18,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":50},"100528494","phase-2-surface-electrical-stimulation-for-urinary-incontinence-in-men-treated-for-prostate-cancer-100528494","NCT06161506","Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer","A Phase II Trial of Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer","* INCLUSION CRITERIA:\n* Participants must be male.\n* Participants must have a history of urinary incontinence for at least 6 months after local prostate cancer treatment.\n* Participants must have at least one of the following types of urinary incontinence:\n\n  * stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities) or on sneezing or coughing\n  * urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.\n* Participants must have moderate urinary incontinence defined as use of 1-4 pads per day by self-report at screening.\n* Participants must be able to read and write in English.\n* Age \\>= 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C= 2.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Change of therapy for prostate cancer planned during the study intervention.\n* History or symptoms of urinary retention (not an exclusion if this occurred before prostatectomy), extra-urethral incontinence, overflow incontinence.\n* Active urinary tract infection (UTI) at screening or history of recurrent urinary tract infections (\\>= 4 UTIs within the 12 months prior to the study treatment initiation).\n* History of complete denervation of the pelvic floor.\n* Severe obesity (body mass index \\[BMI\\] \\>35).\n* Pelvic pain\u002Fpainful bladder syndrome.\n* Metal implant in the abdominal or pelvic area.\n* History of chronic cough with ongoing symptoms\n* An implanted cardiac device, history of untreated cardiac arrhythmia, or history of other heart problems.\n* History of epilepsy.\n* History of underlying neurologic\u002Fneuromuscular disorder that could contribute to urinary incontinence.\n* Change in medications prescribed for urinary incontinence within 2 weeks prior to the study treatment initiation.\n* Uncontrolled intercurrent illness evaluated by medical history and physical examination or social situations that would limit compliance with study requirements.","MALE","120 Years",{"count":191,"type":22},41,[193],"PHASE2","Background:\n\nMen who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help.\n\nObjective:\n\nTo see if the Elidah device can reduce urinary incontinence after prostate treatment.\n\nEligibility:\n\nMen aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer.\n\nDesign:\n\nParticipants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests.\n\nThe Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis.\n\nParticipants will be given an Elidah device and taught how to use it at home.\n\nThey will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks.\n\nParticipants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads.\n\nParticipants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used.\n\nParticipants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment.\n\nParticipants will complete 15-minute questionnaires.",[196,29,197],"Urinary Urge Incontinence","Prostatic Hyperplasia",[199,31,200],"Elidah Device","Prostate Cancer","2026-04-14",{"date":203,"type":42},"2026-04-15",{"date":205,"type":42},"2024-02-15",{"date":207,"type":22},"2028-03-01",{"name":209,"class":210},"National Cancer Institute (NCI)","NIH",{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":229,"leadSponsor":231,"locationsCount":233},"100631468","phase-4-prophylactic-antibiotics-for-outpatient-urethral-bulking-100631468","NCT07501065","Prophylactic Antibiotics for Outpatient Urethral Bulking","Prophylactic Antibiotics for Outpatient Urethral Bulking: Impact on Post-Procedural Urinary Tract Infection Rates","Inclusion Criteria:\n\n* Women ≥ 18 years of age.\n* Patients evaluated by a pelvic floor specialist (either urogynecologist or urologist) at the University of Miami with plans to undergo urethral bulking with Bulkamid for stress urinary incontinence or mixed urinary incontinence (stress predominant).\n* Negative testing for UTI in pre-procedural work-up (including either negative urine culture or urine dip negative for infection).\n* Post-void residual volume of 150 mL or less (measured by either catheterization or bladder scan)\n* Fluent in English or Spanish\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Contraindications to both oral antibiotics including antibiotic allergies or significant renal disease (GFR \\\u003C30)\n* Patient undergoing additional pelvic organ prolapse procedures or other urologic procedures concomitantly\n* Recurrent UTIs, defined as 3 or more UTIs within the past 12 months or 2 UTIs within the past 6 months\n* Patients currently taking daily antibiotic prophylaxis for any reason\n* Pelvic organ prolapse stage greater than 2\n* Patients with immunosuppression due to underlying medical conditions\n* Patients who are pregnant\n* Recent antibiotic treatment within one week of the procedure\n* Unable or unwilling to provide informed consent or complete study procedures",{"count":219,"type":22},150,[221],"PHASE4","The purpose of this study is to evaluate whether taking prophylactic (preventative) antibiotics at the time of standard of care clinic-based urethral bulking reduces the risk of post-procedural urinary tract infection (UTI).",[224,29,31],"Urinary Tract Infections","2026-03-24",{"date":227,"type":42},"2026-03-30",{"date":97,"type":22},{"date":230,"type":22},"2028-12",{"name":232,"class":49},"University of Miami",2,{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":241,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":50},"100627992","impact-of-virtual-reality-pelvic-floor-training-on-postpartum-stress-urinary-incontinence-100627992","NCT07455838","Impact of Virtual Reality Pelvic Floor Training on Postpartum Stress Urinary Incontinence","Impact of Virtual Reality Pelvic Floor Training on Postpartum Stress Urinary Incontinence: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Females, aged 22-35 years.\n* Postpartum period: between 3 and 6 months after vaginal delivery .\n* Able to perform basic pelvic floor contractions (Oxford Grade ≥ 2).\n* Women who are multiparous(2-3times) and have delivered vaginally.\n* Postpartum women with body mass index 18.5-30 kg\u002Fm²\n\nExclusion Criteria:\n\n* Females Diagnosed with neurological conditions affecting pelvic control (e.g., multiple sclerosis, spinal cord injury).\n* History of pelvic floor surgery within the past 12 months.\n* Known visual, vestibular, or cognitive impairments that interfere with VR use.\n* Susceptibility to motion sickness or vertigo, worsened by visual simulation.","22 Years","35 Years",{"count":21,"type":22},[25],"This study will be conducted to determine the effect of virtual reality (VR) on pelvic floor training on postpartum stress urinary incontinence (SUI) .",[29],"2026-03-03",{"date":249,"type":42},"2026-03-06",{"date":251,"type":22},"2026-03-10",{"date":253,"type":22},"2026-05-31",{"name":101,"class":49},{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":23,"phases":264,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":50},"100508449","effect-of-peri-urethral-stimulation-on-intra-urethral-pressure-100508449","NCT05900570","Effect of Peri-Urethral Stimulation on Intra-Urethral Pressure","The Effect of Acute Peri-Urethral Neurostimulation on Intra-Urethral Pressure In Women With Stress Urinary Incontinence (SUI) - Urodynamic Early Feasibility Study","Inclusion Criteria:\n\n* Female aged 18 years old or older\n* Capable of understanding the clinical study procedures and giving informed consent\n* Willing and able to undergo the study procedure\n* Diagnosis of SUI or stress predominant mixed incontinence, for at least 6 months\n* Provided authorization to use and disclose information for research purposes\n\nExclusion Criteria:\n\n* Predominant urge incontinence per patient report or medical record\n* Active symptomatic uncontrolled bladder instability as determined by the investigator\n* Regularly or intermittently used a urethral catheter\n* Active bladder cancer (currently undergoing or scheduled to undergo treatment for bladder cancer).\n* Previous radiation treatment in the pelvic floor\n* History or symptoms of cystocele, enterocele or rectocele of grade 3 or 4. Per the medical record or as determined by the investigator\n* Current infection (urethritis, cystitis or vaginitis) as determined by investigator.\n* Active herpes genitalis\n* Unevaluated hematuria\n* Currently taking, or has taken within 4 weeks prior to the screening\u002Fbaseline visit, pharmacological treatment for SUI (including but not limited to, alpha adrenergics, and tricyclic antidepressants)\n* Severe or uncontrolled diabetes, (defined as being a diabetic with a hemoglobin A1c of ≥10%) per patient medical record.\n* History of drug\u002Falcohol abuse, mental dysfunction, or other factors limiting her ability to cooperate fully\n* Pregnancy test with positive result during screening or women who are breastfeeding\n* Women who are pregnant and\u002For have given birth in the previous 12 months\n* Have implanted active neurostimulators, pacemakers, or defibrillators; neurostimulators which are passive or that can be briefly turned off for the stimulation procedure are acceptable\n* Known systemic neurological dysfunctions\n* Severe coagulation disorders\n* Medically unstable at time of study and unsafe to undergo urodynamic testing (UDT) as determined by the investigator\n* Presence of an artificial urinary sphincter\n* Any medical condition (e.g. Multiple Sclerosis, spinal cord injury, mobility) or uncontrolled chronic disease (e.g. renal diseases that requires dialysis) that would interfere with the patient's ability to comply with the protocol and\u002For may affect the outcome of this study or safety of the subject as determined by the investigator",{"count":263,"type":22},20,[25],"The purpose of this early feasibility prospective study is to gain initial understanding of the effect of acute peri-urethral neurostimulation on the perineal nerves on intra-urethral pressure.",[29],"2025-12-05",{"date":269,"type":42},"2025-12-11",{"date":271,"type":42},"2024-02-26",{"date":273,"type":22},"2027-01",{"name":275,"class":49},"Corewell Health East",{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":283,"minAge":18,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":297,"locationsCount":50},"100372766","btl-emsella-chair-versus-sham-for-the-treatment-of-stress-urinary-incontinence-100372766","NCT04133675","BTL Emsella Chair Versus Sham for the Treatment of Stress Urinary Incontinence","A Single-Blind, Randomized Study of the BTL EmsellaTM Chair Versus Sham for the Treatment of Stress Urinary Incontinence","Inclusion Criteria:\n\n1. Able to read, understand, and provide written, dated, informed consent prior to screening, and be likely to comply with study protocol, including independently complete study questionnaires and communicate with study personnel about AEs and other clinically important information.\n2. Females and males, 18 to 80 years of age, inclusive, at screening\n3. Positive Cough or Bladder Stress Test at screening\n4. Subject agrees not to start any new treatment (medication or otherwise) during the treatment and follow-up periods.\n\n6\\. Subject agrees to maintain a stable dose of any medication known to affect lower urinary tract function, including but not limited to anticholinergics, tricyclic antidepressants, beta-3 adrenergic agonist, or α-adrenergic blockers, throughout the treatment and follow-up periods.\n\nFor Females Only:\n\n* Subject agrees to discontinue use of bladder support devices, including but not limited to vaginal pessary, during the screening, treatment, and follow-up periods.\n* If of child-bearing age and female, agree to practice approved birth-control methods (oral contraceptives, condom barrier, injection, diaphragm or cervical cap, vaginal contraceptive ring, IUD, implantable contraceptive, surgical sterilization (bilateral tubal ligation), vasectomized partner(s))\n\nFor Males Only:\n\n\\- Subject must be ≥ 4 months post radical prostatectomy\n\nExclusion Criteria:\n\n1. Pelvic floor physical therapy, including muscle training and\u002For electrostimulation, in a clinical setting within 30 days prior to screening\n2. Subject is morbidly obese (defined as body mass index 40 or greater)\n3. Pulmonary insufficiency, defined as difficulty breathing and fatigue, especially during exercise; chest pain, such as squeezing, pressure or tightness; the sensation of rapid or irregular heartbeat (palpitations); swelling of the legs or feet; dizziness or fainting; and\u002For bluish discoloration of the nails and\u002For lips (cyanosis)\n4. Any condition that causes a lack of normal skin sensation to the pelvis, buttocks, and lower extremities\n5. Implanted cardiac pacemaker or metal in the body, including, but not limited to drug pumps, neurostimulators, electronic implants, copper intrauterine devices (IUDs), and\u002For defibrillators\n6. Subject has a piercing between the waist and knees and is not willing to remove it before each treatment\n7. Active urethral diverticula\n8. Known vesicoureteral reflux\n9. Currently healing from surgical procedures where muscle contraction may disrupt the healing process\n10. Treatment with urethral bulking agents within the 6 months prior to the Screening Visit\n11. Subject is currently receiving treatment for a malignant tumor that would interfere with study participation.\n12. Subject has used the BTL EMSELLA device previously\n13. Subject has urinary incontinence of neurogenic etiology, such as multiple sclerosis, spina bifida, Parkinson's, spinal cord injury, diabetic neuropathy etc.\n14. Clinically confirmed urinary tract infection, requiring treatment as determined by the investigator, at the Screening Visit\n15. Currently participating in an investigational study that may impact study results or previously received an investigational drug or treatment within 30 days of the Screening Visit\n16. Current or history of any physical condition that, in the investigator's opinion, might put the subject at risk or interfere with study results interpretation\n\n    For Females Only:\n17. Pregnant, or planning to become pregnant, at screening or anytime throughout the study period\n18. History of surgery with insertion of vaginal mesh for SUI\n19. Vaginal prolapse beyond the introitus\n20. Vaginal rejuvenation treatment, including laser treatments and radiofrequency therapy, within the 6 months prior to the Screening Visit\n\n    * Note for the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.","ALL","80 Years",{"count":286,"type":22},110,[25],"Stress urinary incontinence (SUI) is a condition that affects both men and women. SUI is the involuntary leakage of urine caused by an increase in intra-abdominal pressure from activities such as exercise, coughing, laughing, or sneezing. It can significantly affect quality of life as patients avoid activities or behaviors that cause leakage. This clinical trial will compare the efficacy of the Emsella chair to sham and determine if electromagnetic technology is effective in the treatment of SUI.",[29],[291,292],"urinary incontinence","urine leakage",{"date":269,"type":42},{"date":295,"type":42},"2019-12-18",{"date":230,"type":22},{"name":275,"class":49},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":50},"100570370","phase-4-assessing-the-utility-of-prophylactic-antibiotics-at-time-of-urethral-bulking-using-bulkamid-bulkamid-study-100570370","NCT06706362","Assessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid (Bulkamid Study)","Assessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid","Inclusion Criteria\n\n* Patients evaluated by a pelvic floor specialist (either urogynecologist or urologist) at The Ohio State University with plans to undergo urethral bulking with Bulkamid for stress urinary incontinence or mixed urinary incontinence (stress predominant).\n* Negative testing for UTI in pre-operative work-up (including either negative urine culture or urine dip negative for infection).\n* Office evaluation with evidence of SUI either with urodynamic studies (UDS) or positive cough stress test (CST).\n* Post-void residual volume of 150 mL or less (measured by either catheterization or bladder scan)\n\nExclusion Criteria\n\n* Contraindications to both oral antibiotics including antibiotic allergies or significant renal disease\n* Patient undergoing additional pelvic organ prolapse procedures or other urologic procedures concomitantly\n* Recurrent UTIs, defined as 3 or more UTIs within the past 12 months or 2 UTIs within the past 6 months\n* Patients currently taking daily antibiotic prophylaxis for any reason\n* Non-English speaking patients\n* Pregnant patients\n* Pelvic organ prolapse stage greater than 2\n* Patients with immunosuppression due to underlying medical conditions\n* Recent antibiotic treatment within one week of the procedure","50 Years",{"count":307,"type":22},138,[221],"The primary aim of this study is to assess the utility of prophylactic oral antibiotics at time of Bulkamid transurethral bulking to reduce the incidence of urinary tract infection (UTI) in the immediate postoperative period. The secondary aims of the study include assessing UTI rates and success rates if patients require temporary indwelling catheter versus intermittent self-catheterization (ISC).",[29],[312,313,314,315,316],"Bulkamid","Urinary tract infections","Bactrim","Macrobid","Urethral bulking","2025-10-02",{"date":319,"type":42},"2025-10-08",{"date":321,"type":42},"2025-09-15",{"date":323,"type":22},"2027-10-15",{"name":325,"class":49},"Ohio State University",{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":332,"sex":17,"minAge":18,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":336,"conditions":337,"keywords":345,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":50},"100606457","pelvic-floor-disorder-symptoms-in-women-seeking-weight-loss-therapy-100606457","NCT07175805","Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy","Inclusion Criteria:\n\n* female\n* 18-89 years old\n* any race\u002Fethnicity\n* BMI ≥30 kg\u002Fm2\n* current medical weight loss or surgical weight loss patient of Obesity Medicine and Metabolic \\& Bariatric Surgery\n* able\u002Fwilling to give informed consent\n* have a home scale to measure weight\n\nPatients meeting all the following criteria will be eligible to participate in the medical weight loss therapy arm:\n\n* prescribed and start a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a GLP-1\u002Fgastric inhibitory peptide (GIP1)\n* taking other weight loss agents (such as metformin)\n\nPatients meeting all the following criteria will be eligible to participate in the bariatric surgery arm:\n\n* plan to undergo gastric sleeve or gastric bypass surgery\n* taking weight loss agents which are not GLP-1 RA or GLP-1\u002FGIP1 medications at the start of the study. Patients will not be excluded if they are started on GLP-1 RA or GLP-1\u002FGIP1 medications after surgery.\n\nExclusion Criteria:\n\n* Pregnant\n* ≥90 years old\n* \\\u003C18 years old\n* BMI \\\u003C30 kg\u002Fm2\n* A history of bariatric surgery prior to enrollment\n* No home scale to measure weight\n* Active cancer",true,"90 Years",{"count":335,"type":22},200,"The purpose of this study is to compare change in pelvic floor symptoms between patients receiving medical therapy for weight loss and surgical treatment for weight loss. Examples of pelvic floor symptoms include urinary incontinence, urinary urgency, urinary frequency, fecal incontinence, and vaginal prolapse. Participants in this study do not need to have any pelvic floor symptoms to enroll in the study. Understanding how different types of weight loss treatment impact pelvic floor symptoms will help clinicians guide which weight loss treatments are recommended for patients with pelvic floor symptoms in the future.",[338,29,339,340,64,341,342,343,344],"Lower Urinary Tract Symptoms","Urge Urinary Incontinence","Overactive Bladder","Weight Loss","Fecal Incontinence","Bariatric Surgery","glp1 Agonist",[346,347,348,349,350,351,352,353,354],"lower urinary tract symtpoms","stress urinary incontinence","urge urinary incontinence","overactive bladder","pelvic organ prolapse","weight loss","fecal incontinence","bariatric surgery","glp1 agonist",{"date":356,"type":42},"2025-09-16",{"date":358,"type":22},"2025-10",{"date":360,"type":22},"2027-06",{"name":362,"class":49},"Hartford HealthCare",{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":23,"phases":372,"briefSummary":373,"conditions":374,"keywords":375,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":389},"100421771","desara--one-single-incision-sling-522-study-100421771","NCT04772131","Desara ® One Single Incision Sling 522 Study","Prospective, Post-market Study of the Desara® One Single Incision Sling vs. Desara® Blue Sling Implanted Via the Transobturator Route for the Treatment of Women With Stress Urinary Incontinence","Inclusion Criteria:\n\n1. Female ≥ 18 of age.\n2. Subject agrees that she is willing and able to return for all study related procedures and evaluations.\n3. Subject has provided signed informed consent.\n4. Subject has stress urinary incontinence (SUI) confirmed by either supine or standing cough stress test (CST) with bladder pre-fill to subjective fullness with 200-300 mL, or with bladder fullness confirmed via ultrasound.\n5. Subject has confirmed stress incontinence greater than urge incontinence per MESA questionnaire.\n6. Subject no longer has childbearing capacity or has a negative pregnancy test and has decided to cease childbearing. Childbearing capacity to be confirmed by documented history of:\n\n   1. A hysterectomy or\n   2. Tubal ligation or\n   3. Is otherwise incapable of pregnancy or has\n   4. Negative pregnancy test prior to study entry and has decided to cease childbearing\n7. Subject has been offered and either failed or refused alternative non-invasive SUI treatment options and has elected to proceed with a surgical intervention.\n8. Subject is eligible to undergo laparoscopic\u002Frobotic (with or without mesh) or vaginal (with or without mesh) apical, anterior or posterior prolapse concomitant surgical repair procedures (non-mesh).\n\nExclusion criteria:\n\n1. Subject reports baseline pelvic pain ≥ 2 on 10 point Numeric Rating Scale (NRS).\n2. Subject has a known neurological disease (with or without signs\u002Fsymptoms of neurogenic bladder).\n3. Subject has known pre-existing pain syndrome and\u002For has been evaluated by an interventional pain management physician.\n4. Subject has a history of chronic opioid, or narcotic use for:\n\n   1. pain or\n   2. any other specified reason\n5. Subject is on anti-coagulation therapy that cannot be suspended or adjusted for a minimum of 24-48 hours prior to planned sling implantation surgery.\n6. Subject is on chronic (\\> 3 months) systemic steroid treatment (except for inhalational use as indicated for pulmonary conditions).\n7. Subject has uncontrolled diabetes defined as A1c ≥ 7% or fasting serum glucose \\> 130mg\u002Fdl at screening\u002Fbaseline.\n8. Subject has an active lesion or skin infection of the perineum, urethra, or vagina as noted per visual pelvic exam.\n9. Subject has active UTI which requires treatment, as determined by the Investigator.\n10. Subject has pattern of recurrent UTIs, defined as ≥ 3 culture-proven UTIs during the 6-month period prior to surgery.\n11. Subject has a urethral obstruction or other anatomic defects of the urethra (inclusive of urethral diverticulum or stricture or bladder neck contracture).\n12. The subject has had:\n\n    1. any prior surgical stress urinary incontinence treatment or\n    2. any prior surgery on their urethra or\n    3. any prior surgery to distal anterior vaginal wall, including fistula repair or prior cystocele repair\n    4. any previous pelvic floor mesh use or complication\n13. Subject has any of the following confounding conditions:\n\n    1. bladder stones or tumors\n    2. pathology that in the opinion of the Investigator would compromise implant placement\n    3. pathology that would limit pelvic blood supply\n    4. pathology that would require chemotherapy and systemic use of immunosuppressants\n14. Subject has abnormal bladder capacity \\\u003C300 mL.\n15. Subject has a post void residual volume ≥ 150 mL on two different measurements. (Prolapse reduction during PVR measurement is only allowed if a prolapse repair will be performed concomitantly with the sling implantation)\n16. Subject has had previous radiation therapy or brachytherapy to the pelvis.\n17. Subject is enrolled in a concurrent clinical trial of any treatment (drug or device) that could affect continence function, interfere with clinical outcomes, or impact analysis of this device.\n18. Subject has known reaction, sensitivity or allergy to polypropylene.",{"count":371,"type":22},300,[25],"A post-market study to compare the safety and effectiveness of the Desara® One Single Incision Sling (SIS), when compared to that of an FDA cleared transobturator sling over a period of 36 months.",[29],[347,376,377,378,379,380],"female stress urinary incontinence","single incision sling","transobturator sling","Desara® One","Desara® Blue",{"date":382,"type":42},"2025-09-19",{"date":384,"type":42},"2021-11-01",{"date":386,"type":22},"2026-11",{"name":388,"class":78},"Caldera Medical, Inc.",15,{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":397,"enrollmentInfo":398,"targetDuration":4,"studyType":23,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":50},"100458874","efficacysafety-of-midurethral-sling-100458874","NCT05255289","Efficacy\u002FSafety of Midurethral Sling","Evaluation of Efficacy and Safety of Midurethral Slings in Women With Stress Incontinence","Inclusion Criteria:\n\n* Clinical diagnosis of stress urinary incontience\n* Have urodynamic investigations before and after operation.\n\nExclusion Criteria:\n\n* Exclusion criteria will be a history of (1) cardiovascular, (2) neurological, or (3) other medical (such as diabetes or inflammation) problems as well as (4) patients who received a concomitant surgical procedure.","100 Years",{"count":335,"type":22},[25],"The trans-obturator tape (TOT), which exhibits a satisfactory cure rate and a relatively diminished invasiveness, has been increasingly accepted as a surgical treatment of stress urinary incontinence (SUI) patients. Nevertheless, in contrast to the well-recognized therapeutic benefit of the enhanced resistance to the bladder continence during urine storage, if the voiding function of the bladder adapts to the TOT-enhanced outlet resistance has not been adequately investigated. This study retrospectively assayed the voiding efficacy of each voiding cycle, to clarify if the thermodynamic efficacy of the bladder was modified in response to the TOT surgery.",[29],"2025-08-30",{"date":404,"type":42},"2025-09-05",{"date":406,"type":42},"2021-03-08",{"date":408,"type":22},"2026-03",{"name":410,"class":49},"Mackay Medical College",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":332,"sex":17,"minAge":418,"maxAge":419,"enrollmentInfo":420,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":423,"conditions":424,"keywords":425,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":435,"leadSponsor":437,"locationsCount":50},"100602635","effect-of-coping-training-on-attitudes-sleep-and-quality-of-life-in-women-with-stress-urinary-incontinence-100602635","NCT07126080","Effect of Coping Training on Attitudes, Sleep, and Quality of Life in Women With Stress Urinary Incontinence","The Effect of Coping Training on Urinary Incontinence Attitudes, Sleep, and Quality of Life in Postmenopausal Women With Stress Urinary Incontinence: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Female\n* Having entered menopause\n* Volunteering to participate in the study\n* Having no communication barriers\n* Using a smartphone\n* Having the WhatsApp application\n* Experiencing urine leakage when coughing or sneezing, as defined by the ICS (International Continence Association)\n\nExclusion Criteria:\n\n* Having a communication barrier\n* Not having gone through menopause\n* Not experiencing urinary incontinence\n* Having undergone surgical menopause\n* Being obese","45 Years","55 Years",{"count":421,"type":22},96,[25],"This study aims to examine the effects of urinary incontinence management training provided to postmenopausal women on their urinary incontinence attitudes, sleep, and quality of life.\n\nHypothesis H1: Following the urinary incontinence management training, there will be an increase in urinary incontinence attitudes, sleep, and quality of life in the women in the experimental group compared to the women in the control group.",[29],[426,29,427,428,429,430],"Postmenopausal","coping strategies","health quality","Attitude","Sleep Quality","2025-08-15",{"date":433,"type":42},"2025-08-17",{"date":431,"type":22},{"date":436,"type":22},"2026-06-15",{"name":438,"class":49},"Ondokuz Mayıs University",{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":23,"phases":448,"briefSummary":449,"conditions":450,"keywords":453,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":50},"100587135","effect-of-modified-mesh-on-surgical-success-in-transobturator-tape-surgery-100587135","NCT06924450","Effect of Modified Mesh on Surgical Success in Transobturator Tape Surgery","MOTOT","Inclusion Criteria:\n\n* Female patients aged 18 years or older\n* Clinical diagnosis of stress urinary incontinence (SUI), confirmed by:\n* Positive stress test (urine leakage on coughing with a comfortably full bladder)\n* Q-tip test showing urethral hypermobility (\\>30 degrees)\n* Inadequate response to conservative therapy (e.g., pelvic floor muscle training, behavioral therapy)\n* Eligible for transobturator tape (TOT) surgery\n* Body mass index (BMI) less than 35 kg\u002Fm²\n* Able to provide informed consent and follow postoperative instructions\n\nExclusion Criteria:\n\n* History of prior midurethral sling surgery\n* Mixed urinary incontinence or urge-dominant symptoms\n* Pelvic organ prolapse stage \\> II according to the POP-Q system\n* Neurological disorders affecting bladder function (e.g., multiple sclerosis, spinal cord injury)\n* Active urinary tract infection or recurrent UTI (defined as ≥3 infections within the past 12 months)\n* Pregnant or planning to become pregnant within the next 12 months\n* Severe comorbid conditions (e.g., uncontrolled diabetes mellitus, active malignancy, pelvic radiotherapy)\n* Use of medications that significantly affect bladder function (e.g., anticholinergics, diuretics)\n* Inability or unwillingness to attend follow-up visits or comply with postoperative care plan",{"count":447,"type":22},106,[25],"This study is a single-blind, randomized controlled trial evaluating whether changing the width of the surgical tape (mesh) used in transobturator tape (TOT) surgery improves treatment results in women with stress urinary incontinence (SUI). Two mesh widths are being compared: a 1.2 cm mesh (new method) and a 1.0 cm mesh (standard method). The main goal is to find out if the wider mesh leads to better urinary control and fewer complications. Participants will be followed for one year to measure cure rates, symptom improvement, and satisfaction.",[29,451,452],"Female Urinary Incontinence","Pelvic Floor Dysfunction",[31,454,455,456,457,458,459,460],"Stress Urinary Incontinence (SUI)","Female Pelvic Health","Transobturator Tape (TOT) Procedure","Pelvic Floor Surgery","Surgical Mesh","Randomized Controlled Trial","Urogynecology","2025-07-08",{"date":463,"type":42},"2025-07-11",{"date":465,"type":42},"2025-05-12",{"date":467,"type":22},"2025-11-12",{"name":469,"class":49},"Izzet Celegen",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":50},"100486623","laparoscopic-burch-colposuspension-versus-modified-burch-colposuspension-100486623","NCT05616481","Laparoscopic Burch Colposuspension Versus Modified Burch Colposuspension","Laparoscopic Burch Colposuspension Versus Modified Burch Colposuspension For Treatment Of Female Stress Urinary Incontinence; Randomized Controlled Trial","Inclusion Criteria:\n\n* Women with genuine stress urinary incontinence.\n* Mixed urinary incontinence with predominant stress element.\n* Refractory cases to conservative therapy or patients who are not willing to consider (further) conservative treatment.\n\nExclusion Criteria:\n\n* Mixed incontinence with predominant Urge urinary incontinence.\n* Recent pelvic surgery (less than 3 months).\n* Neurogenic lower urinary tract dysfunction.\n* Previous surgery for stress urinary incontinence.\n* Pregnancy\n* Less than 12 months post-partum.\n* Other gynaecologic pathologies affecting bladder functions ( eg, fibroids, ovarian cysts)\n* Genito-urinary malignancy.\n* Current chemo or radiation therapy.",{"count":478,"type":22},120,[25],"This study aims to compare the success rate and complications following laparoscopic standard Burch colposuspension and laparoscopic modified Burch colposuspension (Transobturator tape like)",[29,482],"Burch Colposuspention",[484,485,486],"Stress urinary incontinence","Burch Colposuspension","TOT","2025-05-23",{"date":489,"type":42},"2025-05-29",{"date":491,"type":42},"2022-01-01",{"date":493,"type":22},"2025-07",{"name":495,"class":49},"Al-Azhar University",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":503,"enrollmentInfo":504,"targetDuration":4,"studyType":23,"phases":506,"briefSummary":507,"conditions":508,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":50},"100488096","optimized-acupuncture-treatment-for-female-stress-urinary-incontinence-100488096","NCT05635669","Optimized Acupuncture Treatment for Female Stress Urinary Incontinence","Optimized Acupuncture Treatment for Female Stress Urinary Incontinence: a Study Protocol for a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with mild to moderate SUI mentioned in the diagnostic criteria above;\n* Aged 40～75 years;\n* Sign the informed consent.\n\nExclusion Criteria:\n\n* Other types of urinary incontinence (urgent, overflow or mixed).\n* History of urinary incontinence surgery or pelvic floor surgery;\n* Pelvic organ prolapse ≥ stage II;\n* Symptomatic urinary tract infection;\n* Residual urine volume \\> 30 mL;\n* Maximum urinary flow rate \\\u003C 20ml\u002Fs.\n* Limitation of movement (walk and\u002For run and\u002For climb stairs);\n* Patients who have been using drugs that may affect bladder function or receiving SUI specialized treatment;\n* Severe cardiovascular, cerebral, liver, kidney and hematopoietic system disease, mental disorders, diabetes, multiple system atrophy, cauda equina neuropathy and spinal cord disease;\n* Pregnancy or lactation period.\n* With cardiac pacemaker, acupuncture phobia or metal allergies;","75 Years",{"count":505,"type":22},360,[25],"This multicenter randomized controlled trial is designed to explore a relatively suitable application of acupoint combinations and to provide certain clinical evidence for the optimization of acupuncture treatment of female SUI.",[29],"2025-05-19",{"date":511,"type":42},"2025-05-22",{"date":513,"type":42},"2023-01-04",{"date":515,"type":22},"2026-12",{"name":517,"class":49},"Yin Ping",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":23,"phases":526,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":50},"100536200","the-effectiveness-of-prophylactic-antibiotics-for-urethral-bulking-100536200","NCT06261736","The Effectiveness of Prophylactic Antibiotics for Urethral Bulking","Inclusion Criteria:\n\n* Patients scheduled to undergo a urethral bulking procedure\n* Age 18 ≥ over\n\nExclusion Criteria:\n\n* History of recurrent urinary tract infections\n* Known history of urinary retention\n* Allergies or contraindications to multiple antibiotics\n* Inability to tolerate oral antibiotics\n* Concomitant surgical procedures at the time of urethral bulking\n* Pregnant or breastfeeding",{"count":525,"type":22},70,[25],"The goal of this clinical trial is to evaluate if prophylactic antibiotics in urethral bulking are effective in reducing postprocedural urinary tract infections.",[29,529,530],"Postoperative Urinary Tract Infection","Urethral Bulking","2025-04-04",{"date":533,"type":42},"2025-04-08",{"date":535,"type":42},"2023-10-24",{"date":537,"type":22},"2026-01",{"name":539,"class":49},"Atlantic Health System",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":546,"enrollmentInfo":547,"targetDuration":4,"studyType":23,"phases":549,"briefSummary":550,"conditions":551,"keywords":555,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":50},"100580653","outcomes-of-limited-postoperative-restrictions-following-sling-placement-a-randomized-controlled-trial-100580653","NCT06840093","Outcomes of Limited Postoperative Restrictions Following Sling Placement: A Randomized Controlled Trial","Inclusion: Undergoing isolated synthetic mesh retropubic midurethral sling placement Exclusion criteria: Non-English speaking, incarcerated, cognitive impairment precluding informed consent, unable to ambulate without the assistance of an ambulation device, concurrent prolapse procedure","99 Years",{"count":548,"type":22},84,[25],"The purpose of this research study is to better understand optimal restrictions for patients postoperatively following a mesh urethral sling placement for patients with stress urinary incontinence.\n\nPatients undergoing a midurethral sling procedure will be assigned to one of two groups. One group with be given standard postprocedural restrictions including instructions to avoid moderate activity and no lifting over 15lbs for six weeks after surgery. The other group will have fewer restrictions, with no restrictions on activity or lifting.\n\nParticipants will complete surveys at 2 weeks, 3 months and 1 year following their procedure to help providers better understand how patients are following postoperative restrictions and if there were any differences in the outcome of the procedure between the two groups.",[552,553,554,29],"Postoperative Restriction","Midurethral Sling","Mesh",[556,167,557,347],"postoperative restrictions","mesh","2025-03-26",{"date":560,"type":42},"2025-04-01",{"date":562,"type":42},"2025-03-01",{"date":564,"type":22},"2027-06-30",{"name":566,"class":49},"University of Iowa",{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":17,"minAge":242,"maxAge":19,"enrollmentInfo":574,"targetDuration":4,"studyType":23,"phases":576,"briefSummary":577,"conditions":578,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":233},"100487487","effectiveness-and-cost-effectiveness-of-pelvisense-a-novel-biofeedback-device-for-stress-urinary-incontinence-in-women-100487487","NCT05627726","Effectiveness and Cost-effectiveness of PelviSense, a Novel Biofeedback Device for Stress Urinary Incontinence in Women","Effectiveness and Cost-effectiveness of PelviSense, a Novel Biofeedback Device With Wearable Sensors for Stress Urinary Incontinence in Women: a Randomised Controlled Trial Alongside Economic Evaluation","Inclusion Criteria:\n\n* non-pregnant women with stress urinary incontinence (SUI),\n* aged 35 to 65 years,\n* women who experience mild to moderate SUI, as indicated by a pad weight gain of 1-50 g during the 1-hour pad test with stress test,\n* women with a score ≥24 on the Mini-Mental State Examination.\n\nExclusion Criteria:\n\n* women \\\u003C6 months postpartum,\n* women with severe pelvic organ prolapse,\n* women with complicated SUI due to pelvic region radiation,\n* women with a body mass index (BMI) ≥30,\n* women with severe psychological problems impairing study participation,\n* women with mixed urinary incontinence (MUI) or urge urinary incontinence (UUI)",{"count":575,"type":22},142,[25],"Aims: (1) Investigate the efficacy of PelviSense-assisted PFMT compared with PFMT alone for improving SUI symptom severity in women; (2) Compare the cost-effectiveness of the PelviSense device against PFMT alone for treating SUI in women; (3) Explore the views of women regarding the use of the PelviSense device as an adjunct to PFMT and the impacts of the PelviSense device on their lives and well-being.\n\nDesign and subjects: A sequential, embedded, experimental mixed-methods design, including a randomised controlled trial (RCT) and semi-structured focus groups, will be conducted alongside an economic evaluation. The proposed study will include 142 women with SUI or stress-predominant mixed urinary incontinence.\n\nInterventions: Women will be randomly allocated to one of two groups (PelviSense or PFMT alone \\[control\\]). The PelviSense group will perform PFMT with assistance from the PelviSense device, and the control group will perform PFMT without biofeedback (i.e., PFMT alone).\n\nOutcome measures: International Consultation on Incontinence Questionnaire-Short Form, one-hour pad test, Modified Oxford Scale, EQ-5D-5L, and electronic cost diary.\n\nData analysis and expected results: Statistical analysis will be conducted using analysis of covariance. The PelviSense group is expected to report significant improvements in primary and secondary outcomes compared with the PFMT alone group. The PelviSense group will yield cost savings and result in lower health care utility compared with the PFMT alone group.",[29],"2025-03-12",{"date":581,"type":42},"2025-03-17",{"date":583,"type":42},"2024-04-01",{"date":585,"type":22},"2026-10-26",{"name":587,"class":49},"The Hong Kong Polytechnic University",{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":332,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":597,"conditions":598,"keywords":599,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":607,"locationsCount":50},"100517763","pessary-experience-study-100517763","NCT06021769","Pessary Experience Study","Longitudinal Assessment of Pessary Experience","Inclusion Criteria:\n\n* English-speaking women aged 18 years or older\n* Choosing to undergo a pessary fitting for symptomatic pelvic organ prolapse and\u002For stress urinary incontinence at the University of Virginia Pelvic Medicine and Reconstructive Surgery clinic\n* Willingness and ability to comply with scheduled visits and study procedures.\n* Successful pessary fitting\n\nExclusion Criteria:\n\n* Pregnant women\n* Prisoners\n* Cognitively impaired\n* Non-English speaking subjects\n* Patients who cannot comply with pessary check visits\n* Active vaginal infection\n* Vaginal malignancy\n* Genitourinary tract fistula",{"count":596,"type":22},30,"Pessaries are silicone devices inserted into the vagina for treatment of pelvic organ prolapse or stress urinary incontinence. They are adequate treatment options for patients who are poor surgical candidates, those who decline surgical intervention, or as a temporizing measure in those ultimately planning surgery. Most studies suggest that about 75% of patients are able to be successfully fit with a pessary, but about 50% discontinue pessary use within 12 months of initiation. The purpose of this study is to determine why pessaries are discontinued.",[64,29],[600],"pessary","2025-01-26",{"date":603,"type":42},"2025-01-28",{"date":605,"type":42},"2023-06-12",{"date":515,"type":22},{"name":608,"class":49},"University of Virginia",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":4,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":17,"minAge":305,"maxAge":616,"enrollmentInfo":617,"targetDuration":4,"studyType":23,"phases":618,"briefSummary":619,"conditions":620,"keywords":623,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":632,"locationsCount":4},"100576690","preliminary-outcome-of-tecar-on-stress-urinary-incontinence-pelvic-floor-strength-and-sexual-satisfaction-in-women-with-vaginal-relaxation-syndrome-100576690","NCT06788574","Preliminary Outcome Of Tecar On Stress Urinary Incontinence, Pelvic Floor Strength And Sexual Satisfaction In Women With Vaginal Relaxation Syndrome","Preliminary Outcome Of Tecar Therapy Effect On Stress Urinary Incontinence, Pelvic Floor Strength And Sexual Satisfaction In Women Complaining Of Vaginal Relaxation Syndrome: A Randomized Controlled Trial","Inclusion Criteria:\n\n* participants are multipara at least two times with sexual activity for at least 1\u002Fmonth with normal cell cytology (PAP smear), integrity of the vaginal canal mucosa, and negative urine culture (without injuries or bleeding).\n\nExclusion Criteria:\n\n* pregnancy, use of photosensitive medicines, vaginal bleeding injury or infection in the treated area, and use of an IUD.","60 Years",{"count":89,"type":22},[25],"Forty women aged 50-60 years with a body mass index (BMI) of 25 kg\u002Fm2 to 30 kg\u002Fm2, who complain of stress urinary incontinence and vaginal laxity, will be separated randomly into two equivalent groups. In group (A) 20 women will receive TECAR therapy for 15 min and pelvic floor exercise for 20 min, while in group (B), 20 females will receive sham treatment for 15 min and pelvic floor exercise for 20 min twice per week for 8 weeks. Both groups wil be assessed using a perineometer as an assessment tool for pelvic floor muscle strength muscles and the Visual Analog Scale, ICIQ-UI short form questionnaire about the frequency of urinary incontinence symptoms, Millheiser Sexual Satisfaction Scale, and the Sexual Quality of Life Questionnaire-Female (SQOL-F) to assess sexual satisfaction by each patient before, after 4 weeks, and after 8 weeks of treatment",[621,622],"STRESS URINARY INCONTINENCE","VAGINAL RELAXATION SYNDROME",[624,625],"Vaginal Relaxation Syndrome","Tecar Therapy","2025-01-16",{"date":628,"type":42},"2025-01-23",{"date":630,"type":22},"2025-01-15",{"date":560,"type":22},{"name":101,"class":49},{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":332,"sex":17,"minAge":641,"maxAge":333,"enrollmentInfo":642,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":644,"conditions":645,"keywords":648,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":50},"100572339","the-follow-up-after-shorter-tapes-study-effectiveness-and-safety-of-shorter-trans-obturator-tapes-100572339","NCT06731985","The Follow-up After Shorter Tapes Study. Effectiveness and Safety of Shorter Trans-obturator Tapes.","The FAST- Study: The Follow-up After Shorter Tapes Study Effectiveness and Safety of Shorter Trans-obturator Tapes: A Prospective Observational Study From the Norwegian Female Incontinence Registry","FAST","Inclusion Criteria:\n\n* All women operated for stress-urinary incontinence with TVT-O Abbrevo of Ajust incontinence sling between 2009 and 2020.\n\nExclusion Criteria:\n\n* Women operated with other incontinence operations or slings.","25 Years",{"count":643,"type":22},750,"Urinary incontinence after pregnancy and labor affects 1 in 3 women and has a negative impact on quality of life (QOL), limiting women's physical activity and impairing sexual function. The traditional surgical method treating female urinary incontinence is to implant a sub-urethral synthetic sling, the currently preferred method in Norway. The majority of women treated with synthetic slings obtain great improvement in QOL, but a few experience severe complications including chronic pelvic pain. Several countries, therefore, have reverted to older, less effective surgical methods to avoid synthetic material. Awareness of severe complications has, in some Norwegian hospitals, led to a shift in technique towards shorter slings. With shorter slings, the goal is to achieve the same grade of continence as traditional slings, but with fewer serious complications. The long-term results and complications of these shorter slings are mostly unknown. Akershus University Hospital (AHUS) shifted to shorter slings early, in 2009, using a single incision mini-sling (SIMS) Ajust. Due to costs, AHUS changed to the intermediate sling TVT-O Abbrevo in 2016.\n\nThrough this study, we hope to establish if shorter slings have the same long-term results as traditional slings, and to investigate if shorter slings are safer than traditional slings, with less long-term complications, such as chronic pelvic pain. We plan to perform a long-term follow-up of women having had surgery with shorter slings at AHUS.\n\nAll patients operated with either SIMS Ajust or TVT-O Abbrevo at AHUS between 2009 and 2020 will be invited to a long-term follow-up. The study participants will be asked to fill in validated questionnaires regarding symptoms of urine leakage, QOL, any chronic pain related to the surgery, debut of pain, level of pain and any treatments for the pain. All women treated with the current used sling Abbrevo is invited to a physical examination including testing of their voiding function and a gynecologic examination to check for complications.\n\n2D- and 3D ultrasound scans will be done on the TVT-O Abbrevo group to evaluate the position-, attachment- and any misplacement of the sling.\n\nWomen experiencing insufficient long-term results, such as chronic pain, will be offered a full examination and treatment.",[29,646,647],"Postsurgical Pain","Follow-Up Studies",[649],"Long-term Follow-Up of shorter incontinence tapes","2024-12-09",{"date":652,"type":42},"2024-12-13",{"date":654,"type":42},"2024-10-24",{"date":656,"type":22},"2026-10-31",{"name":658,"class":49},"University Hospital, Akershus"]